Hypermarcas (OTCMKTS:HYPMY) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of Hypermarcas (OTCMKTS:HYPMY) to a hold rating in a research note issued to investors on Wednesday morning,Zacks.com reports.

Hypermarcas Stock Performance

Shares of OTCMKTS:HYPMY opened at $4.69 on Wednesday. The company has a market capitalization of $3.30 billion, a price-to-earnings ratio of 9.77 and a beta of 0.75. Hypermarcas has a 12 month low of $3.71 and a 12 month high of $5.50. The firm’s 50-day moving average is $4.42 and its 200 day moving average is $4.47. The company has a current ratio of 1.27, a quick ratio of 0.84 and a debt-to-equity ratio of 0.61.

Hypermarcas (OTCMKTS:HYPMY) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $0.10 earnings per share (EPS) for the quarter. Hypermarcas had a net margin of 19.41% and a return on equity of 14.08%. The business had revenue of $383.13 million during the quarter. Research analysts predict that Hypermarcas will post 0.53 EPS for the current year.

Hypermarcas Company Profile

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.